AAPL 229.98 0.7535% MSFT 429.03 1.0481% NVDA 137.71 3.0995% GOOGL 196.0 1.6018% GOOG 197.55 1.6151% AMZN 225.94 2.3928% META 612.77 0.2405% AVGO 237.44 3.5003% TSLA 426.5 3.0641% TSM 211.5 -1.5317% LLY 725.72 -4.208% V 319.62 0.747% JPM 259.16 1.9232% UNH 509.76 -0.1626% NVO 78.69 -5.2727% WMT 91.94 0.701% LVMUY 142.08 -1.4497% XOM 112.32 0.8983% LVMHF 710.0 -0.9487% MA 524.7 0.2982%
Last update at 2025-01-17T14:30:00Z
CSPC Pharmaceutical Group And 2 Other Promising Penny Stocks To Watch
Fri 20 Dec 24, 04:11 PMAstraZeneca Inks Agreement to Boost Cardiovascular Pipeline
Tue 08 Oct 24, 05:05 PMAstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline
Mon 07 Oct 24, 12:04 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 7582.26M | 6847.10M | 6391.02M | 4626.16M | 4501.61M |
| Minority interest | -140.66000M | -82.93900M | 768.78M | 1056.44M | 477.34M |
| Net income | 6091.39M | 5605.19M | 5159.65M | 3714.11M | 3654.98M |
| Selling general administrative | 11510.26M | 11453.25M | 10323.33M | 9460.59M | 8108.19M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 22256.41M | 21135.09M | 18685.32M | 15910.98M | 13912.79M |
| Reconciled depreciation | 1047.94M | 865.47M | 808.81M | 691.60M | 655.25M |
| Ebit | - | 6249.26M | 5472.15M | 4449.96M | 3613.72M |
| Ebitda | 8655.09M | 7720.23M | 7212.06M | 5350.18M | 4685.72M |
| Depreciation and amortization | - | - | - | - | - |
| Non operating income net other | - | - | - | - | 0.00000M |
| Operating income | 6759.63M | 6794.95M | 6056.67M | 4600.18M | 4293.01M |
| Other operating expenses | - | 58.20M | 57.04M | 42.02M | 59.57M |
| Interest expense | 24.89M | 7.66M | 12.23M | 32.43M | 76.90M |
| Tax provision | 1350.21M | 1158.97M | 1162.01M | 892.81M | 766.71M |
| Interest income | - | - | - | - | - |
| Net interest income | -24.89100M | -7.66400M | -12.23200M | -32.42600M | -76.90096M |
| Extraordinary items | - | - | - | - | 0.00000M |
| Non recurring | - | - | - | - | 0.00000M |
| Other items | - | - | - | - | 0.00000M |
| Income tax expense | - | 1158.97M | 1162.01M | 892.81M | 733.76M |
| Total revenue | 30936.90M | 27866.87M | 24942.20M | 22103.19M | 21028.87M |
| Total operating expenses | 24177.27M | 21071.92M | 18885.54M | 17503.01M | 16735.87M |
| Cost of revenue | 8680.49M | 6731.78M | 6256.88M | 6192.21M | 7116.08M |
| Total other income expense net | - | - | - | - | 208.60M |
| Discontinued operations | - | - | - | - | 0.00000M |
| Net income from continuing ops | 6232.05M | 5688.12M | 5229.01M | 3733.35M | 3628.62M |
| Net income applicable to common shares | - | 5605.19M | 5159.65M | 3714.11M | 3080.80M |
| Preferred stock and other adjustments | - | - | - | - | 0.00000M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 46282.17M | 41769.77M | 34741.58M | 30070.21M | 26318.32M |
| Intangible assets | 2198.55M | 1908.11M | 467.85M | 508.74M | 1135.66M |
| Earning assets | - | - | - | - | - |
| Other current assets | -170.30935M | - | 177.75M | 36.57M | 562.22M |
| Total liab | 11264.16M | 10127.90M | 7913.35M | 6969.13M | 6800.16M |
| Total stockholder equity | 33203.21M | 30197.53M | 25986.67M | 22332.29M | 18461.72M |
| Deferred long term liab | - |
US 
AU
UK
CA
NZ